arrow
F

Felicitas Thol

Hannover Medical School
H指数:63
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Eltrombopag plus cyclosporine A for moderate aplastic anemia (EMAA): a placebo-controlled, double-blind, phase 3 trial

艾曲波帕联合环孢素A治疗中度再生障碍性贫血(EMAA):一项安慰剂对照、双盲、III期临床试验

Blood
IF23.1
2026-08-200
OAAI
DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy

DECIDER-2:一项前瞻性随机多中心III期临床试验,评估地西他滨联合维奈克拉在所有-trans维甲酸或安慰剂中给予急性髓系白血病患者的疗效,这些患者不适合诱导化疗

2026-08-050
OA
Rapid and Reproducible Karyotyping with Long Read Sequencing in AML Patients

利用长读长测序技术实现急性髓系白血病患者的快速且可重复的核型分析

2026-06-290
OA
International testing and refinement of AI algorithms predicting acute leukemia subtypes from routine laboratory data

从常规实验室数据中预测急性白血病亚型的AI算法的国际测试和改进

2026-03-200
OAAI
Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia

FLT3-ITD突变急性髓系白血病中髓系发育异常相关基因突变的预后影响

Leukemia
IF13.4
2026-02-090
OAAI
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party

2025年急性髓系白血病微小残留病更新:ELN-DAVID微小残留病工作组共识文件

Blood
IF23.1
2025-12-160
OAAI
Resolving intra-tumor heterogeneity and clonal evolution of core-binding factor acute myeloid leukemia patients with single-cell resolution

解析核心结合因子急性髓系白血病患者的肿瘤内异质性和克隆演化的单细胞分辨率研究

2025-10-310
OAAI
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients

4978例接受强化治疗的AML欧洲患者队列中,髓系发育异常相关基因突变的不同预后影响

Leukemia
IF13.4
2025-10-270
OA
CPX-351 in Down Syndrome-associated Myeloid Leukemia: Results and Prognostic Factors from the Phase III ML-DS 2018 Trial

CPX-351在Down Syndrome-associated Myeloid Leukemia中的研究结果及预后因素:来自III期ML-DS 2018试验的数据

Blood
IF23.1
2025-10-240
OAAI
Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial

随机II期DECIDER试验中,急性髓系白血病持续应用脱氧胞苷类似物为基础治疗后,获得性耐药时的遗传和表观遗传改变

Leukemia
IF13.4
2025-10-070
OA
Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy

肾疾病在应用Venetoclax为基础的低强度疗法治疗的初诊急性髓系白血病中的预后作用

2025-09-230
OAAI
Comparison of prognostication by IPSS-M, IPSS-R and AIPSS-MDS in the context of limited availability of molecular data in daily clinical practice

在分子数据在日常临床实践中有限可用的情况下,IPSS-M、IPSS-R和AIPSS-MDS预后预测的比较

2025-09-060
OAAI
Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia

髓系发育不良相关基因突变克隆性表达在急性髓系白血病中的预后影响

LEUKEMIA
IF13.4
2025-04-280
OA
Anti-CD19 CAR-T cell therapy for acquired hemophilia A

CD19嵌合抗原受体T细胞疗法治疗获得性血友病A

LEUKEMIA
IF13.4
2025-03-080
OA
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
2024-12-030
OAAI
Prognostic Impact of Subclinical FLT3-ITD Microclones in Patients with Acute Myeloid Leukemia

亚临床FLT3-ITD微克隆对急性髓系白血病患者预后的影响

BLOOD
IF23.1
2024-11-050
PRE